Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: Pathophysiology and rationale for specific therapy

European Journal of Haematology

Volumn 82, Issue 2, 2009, Pages 83-92

  Sane, David C ^a,b   Streer, Nathan P ^a   Owen, John ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Myocardial infarction; Thrombotic thrombocytopenic purpura; Troponin; Von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; FOLIC ACID; HEPARIN; HIRULOG; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PREDNISONE; RITUXIMAB; STEROID; TICLOPIDINE; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; BARE METAL STENT; BLOOD VESSEL OCCLUSION; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMPLETE HEART BLOCK; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG ELUTING STENT; DRUG INHIBITION; DRUG RELEASE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART ARREST; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART DEATH; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART RUPTURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART TAMPONADE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; MICROVASCULATURE; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERICARDIAL EFFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECURRENT DISEASE; REVIEW; SPLENECTOMY; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; TELEMETRY; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASOSPASM;

HEART DISEASES; HUMANS; MYOCARDIUM; NECROSIS; PURPURA, THROMBOCYTOPENIC;

EID: 58149387545     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01172.x     Document Type: Review

References (86)

1. Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients and patients with severe ADAMTS13 deficiency. J Thromb Haemost 2005 3 : 1432 6.
2. Török TJ, Holman RC, Chroba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States: analysis of national mortality data, 1968-1991. Am J Hematol 1995 50 : 84 90.
3. George JN, Hovinga JAK, Terrell DR, Vesely SK, Lämmle B. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Registry: the Swiss connection. Eur J Haematol 2008 80 : 277 86.
4. Ruutu T, Barosi G, Benjamin RJ, et al. European Group for Blood and Marrow Transplantation; European LeukemiaNet. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007 92 : 95 100.
5. Bell W. Thrombotic thrombocytopenic purpura. JAMA 1991 265 : 91 3.
6. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991 325 : 393 7.
7. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 102 : 60 8.
8. Frawley N, Ng AP, Nicholls K, Cohney S, Hogan C, Grigg A. Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single centre experience. Intern Med J 2008 doi :.
9. Ridolfi RL, Hutchins GM, Bell WR. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. Ann Intern Med 1979 91 : 357 63.
10. James TN, Alperin JB. Apoptotic myocardial degeneration in thrombotic thrombocytopenic purpura. Apoptosis 1997 2 : 384 94.
11. Podolsky SH, Zembowicz A, Schoen FJ, Benjamin RJ, Sonna LA. Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. Arch Pathol Lab Med 1999 123 : 937 40.
12. McCarthy LJ, Danielson CF, Skipworth EM, Peters SL, Miraglia CC, Antony AC. Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. Ther Apher 2002 6 : 2 4.
13. Patschan D, Witzke O, Duhrsen U, Erbel R, Philipp T, Hergot-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies - clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006 21 : 1549 54.
14. Perez L, Ramappa P, Guzman JA. Myocardial injury in thrombotic thrombocytopenic purpura: a frequent, perplexing complication. Int J Cardiol 2008 128 : 257 60.
15. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 2008 2 : 382 92.
16. Wahla AS, Ruiz J, Noureddine N, Upadhya B, Sane DC, Owen J. Myocardial infarction in thrombotic thrombocytopenic purpura. A single-center experience and literature review. Eur J Haematol 2008 81 : 311 16.
17. Babuin L, Jaffe AS. Troponin: the biomarker of choice for detection of cardiac injury. CMAJ 2005 173 : 1191 202.
18. Peacock WF IV., De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. ADHERE Investigators: cardiac troponin and outcome in acute heart failure. N Engl J Med 2008 358 : 2117 26.
19. Blich M, Sebbag A, Attias J, Aronson D, Markiewicz W. Cardiac Troponin I. Elevation in hospitalized patients without acute coronary syndromes. Am J Cardiol 2008 101 : 1384 8.
20. Vischer UM. von Willebrand factor, endothelial dysfunction and cardiovascular disease. J Thromb Haemost 2006 4 : 1186 93.
21. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999 94 : 172 8.
22. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV, Moake JL, Lopze JA. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002 99 : 3971 7.
23. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008 3 : 249 77.
24. Tsai H-M, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 : 1585 94.
25. Tsai H-M. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007 21 : 609 34.
26. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998 339 : 1578 84.
27. Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008 6 : 1233 5.
28. Patton JF, Manning KR, Case D, Owen J. Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol 1994 47 : 94 9.
29. Olson JS, Foley EW, Rogge C, Tsai A-L, Doyle MP, Lemon DD. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004 36 : 685 97.
30. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. A novel mechanism of human disease. JAMA 2005 293 : 1653 62.
31. Studt JD, Hovinga JA, Antoine G, Hermann M, Rieger M, Scheifkinger F, Lämmle B. Fatal congential thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005 105 : 542 4.
32. Wagener FA, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, Abraham NG, Adema G, van Kooyk Y, de Witte T, Figdor CG. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 2001 98 : 1802 11.
33. Olsen SB, Tang DB, Jackson MR, Gomez ER, Ayala B, Alving BM. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation 1996 93 : 327 32.
34. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death. a meta-analysis. JAMA 2008 299 : 2304 12.
35. Heptinstall S, Johnson A, Glenn JR, White AE. Adenine nucleotide metabolism in human blood - important roles for leukocytes and erythrocytes. J Thromb Haemost 2005 3 : 2331 9.
36. Vischer UM, Wollheim CB. Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis. Blood 1998 91 : 118 27.
37. Pinsky DJ, Broekman MJ, Peschon JJ, et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002 109 : 1031 40.
38. Moschowitz E. Hyaline thrombosis of the terminal arerioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924 24 : 21 4.
39. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003 127 : 834 9.
40. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985 38 : 469 79.
41. Katoh M, Shigematsu H. Renal involvement of thrombotic thrombocytopenic purpura: special reference to the glomeruloid structures. Pathol Int 1999 49 : 638 42.
42. Gami AS, Hayman SR, Grande JP, Garovic VD. Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med 2005 118 : 544 7.
43. Wiviott S, de Lemos JA, Morrow DA. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta 2004 346 : 119 28.
44. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002 347 : 589 600.
45. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000 16 : 505 11.
46. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003 91 : 1055 9.
47. Moens AL, Champion HC, Claeys MJ, et al. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 2008 117 : 1810 9.
48. Tian R, Ingwall JS. How does folic acid cure heart attacks? Circulation 2008 117 : 1772 4.
49. Amorosi EL, Karpatkin S. Antiplatelet treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1977 86 : 102 6.
50. Quintini G, Barbera V, Iannitto E, Spadola V, Fadda R, Greco G, Mazzola G, Mariani G. Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura. Transfus Apher Sci 2003 29 : 141 5.
51. Rosove MH, Ho WG, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1982 96 : 27 33.
52. Chakrabarti S, Freedman JE. Dipyrdiamole, cerebrovascular disease and the vasculature. Vascul Pharmacol 2008 48 : 143 9.
53. Zhao L, Gray L, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 2006 17 : 100 4.
54. Kappers-Klunne ML, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, Löwenberg B, Brand A. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005 130 : 768 76.
55. Ziman A, Mitri M, Klupper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion 2005 45 : 41 9.
56. Moake JL, Rudy CK, Troll JH, Schafer AI, Weinstein MJ, Colannino NM, Hong SL. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985 20 : 73 9.
57. Allan DS, Kovacs MJ, Clark WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001 86 : 844 50.
58. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005 106 : 1932 7.
59. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab for immune-mediated disorders. J Clin Apher 2006 21 : 49 56.
60. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999 340 : 409 17.
61. Reynolds JD, Ahearn GS, Angelo M, Zhang J, Cobb F, Stamler JS. S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci USA 2007 104 : 17058 62.
62. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008 358 : 1229 39.
63. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, Tacconi F, Ascari E. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP): results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 1997 82 : 429 36.
64. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-asscoiated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007 50 : 1138 43.
65. Jonas S, Grieco G. Editorial comment- an approach to the estimation of the risk of TTP during clopidogrel therapy. Stroke 2004 35 : 537 8.
66. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002 22 : 1524 34.
67. Fish RJ, Yang H, Viglino C, Schorer R, Dunoyer-Geindre S, Kruithof EKO. Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. Biochem J 2007 405 : 597 604.
68. Seljeflot I, Arnesen H, Andersen P, Aspelin T, Kierulf P. Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J Cardiovasc Pharmacol 1999 34 : 584 8.
69. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 2001 38 (Suppl. 3 513 6.
70. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease. Arch Intern Med 2003 163 : 1155 64.
71. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, Kluft C, Blann A, Cokkinos D, Ferrari R. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study, PERTINENT. Cardiovasc Res 2007 73 : 237 46.
72. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004 351 : 2049 57.
73. Matsushita K, Morrell CN, Cambien B, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide sensitive factor. Cell 2003 11 : 139 50.
74. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemutter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000 36 : 110 4.
75. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman E, Braunwald E. Predictors of the rise in VWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 2005 26 : 440 6.
76. Wagner DD, Bonfanti R. Von Willebrand factor and the endothelium. Mayo Clin Proc 1991 66 : 621 7.
77. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005 105 : 1085 93.
78. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topoe EJ, Manuvkian SV. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 2007 100 : 1364 9.
79. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 355 : 2203 16.
80. Abdelhamed IA, Reis SE, Sane DC, Brosnihan B, Perli RB, Herrington DM. No effect of an L-arginine-enriched medical food (Heartbars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia. Am Heart J 2003 145 : E15.
81. Bonnefoy A, Vermylen J, Hoylaerts MF. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev Cardiovasc Ther 2003 2 : 257 69.
82. Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001 101 : 395 404.
83. Wolfson W. Ablynx makes nanobodies from llama bodies. Chem Biol 2006 13 : 1243 4.
84. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, BouFakhreddine S, Holohan TV, y Schaub RG. First-in-human evaluation of anti-von-Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007 116 : 2678 86.
85. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002 22 : 323 8.
86. Plaimauer B, Zimmermann K, Völkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002 100 : 3626 32.